Moderna says Health Canada has approved its mRNA vaccine, shown in a handout photo, to protect against respiratory syncytial virus in adults age 60 and older. THE CANADIAN PRESS/HO-Moderna **MANDATORY CREDIT**
In a news release, Moderna said it expects the RSV vaccine — called mRESVIA — to be available in early 2025. Earlier this year, the National Advisory Committee on Immunization recommended RSV immunization for adults 75 years and older. According to the Public Health Agency of Canada’s wastewater surveillance, the level of RSV circulating is currently “moderate” across much of the country.
このニュースをすぐに読めるように要約しました。ニュースに興味がある場合は、ここで全文を読むことができます。 続きを読む:
日本 最新ニュース, 日本 見出し
Similar News:他のニュース ソースから収集した、これに似たニュース記事を読むこともできます。
Health Canada approves Moderna's mRNA RSV vaccine, company saysTORONTO — Moderna says Health Canada has approved its mRNA vaccine to protect against respiratory syncytial virus in adults age 60 and older. The company says it expects the RSV vaccine — called mRESVIA — to be available in early 2025.
ソース: SooToday - 🏆 8. / 85 続きを読む »
Health Canada approves Moderna's mRNA RSV vaccine, company saysTORONTO — Moderna says Health Canada has approved its mRNA vaccine to protect against respiratory syncytial virus in adults age 60 and older. The company says it expects the RSV vaccine — called mRESVIA — to be available in early 2025.
ソース: BurnabyNOW_News - 🏆 14. / 77 続きを読む »
Health Canada approves Moderna's mRNA RSV vaccine, company saysTORONTO — Moderna says Health Canada has approved its mRNA vaccine to protect against respiratory syncytial virus in adults age 60 and older. The company says it expects the RSV vaccine — called mRESVIA — to be available in early 2025.
ソース: PGCitizen - 🏆 65. / 51 続きを読む »
Health Canada approves Moderna’s mRNA RSV vaccine, company saysAgency approves the vaccine to protect against respiratory syncytial virus in adults age 60 and older
ソース: globeandmail - 🏆 5. / 92 続きを読む »
Health Canada approves Moderna's mRNA RSV vaccine, company saysTORONTO — Moderna says Health Canada has approved its mRNA vaccine to protect against respiratory syncytial virus in adults age 60 and older. The company says it expects the RSV vaccine — called mRESVIA — to be available in early 2025.
ソース: timescolonist - 🏆 15. / 75 続きを読む »